Clinical trialObservationalRecruiting
Use of Ctdna in Patients With Gastrointestinal Tract Tumors
Prospective Single-center Study About the Use of Ctdna in the Management of Patients With Tumors of the Gastrointestinal Tract
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Recruiting
- Study type
- Observational
- Start
- 1 November 2023
- Expected end
- 1 November 2028
- Enrollment
- 100 participants
- Sites
- 1
- Primary outcomes
- mOS
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 2 September 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study will evaluate the use of ctDNA in the clinical management of patients with tumors of the gastrointestinal tract.
Detailed description public domain (ClinicalTrials.gov)
This is a a prospective observational single-center study; it is a spontaneous study, not sponsored by pharmaceutical companies, and does not involve the use of experimental drugs. The study involves a collection of data, carried out while protecting the anonymity and personal information of individual patients suffering from neoplasms of the gastrointestinal tract, the execution of peripheral blood samples and the collection of faecal material at pre-determined times -points. Circulating biomarkers (as ctDNA) will be evaluated in these samples, in order to optimize both the diagnostic and therapeutic processes of patients with tumors of the gastrointestinal tract.